ACTRN12622000454774已完成未知
A randomised trial of influenza vaccination strategies in patients with haematological malignancy
Peter MacCallum Cancer Centre0 个研究点目标入组 130 人开始时间: 2022年3月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1.Male and female subjects aged greater than or equal to 18 years and currently receiving or have received within last 12 months treatment for MM, CLL and NHL. Women of child-bearing potential will need to be on adequate contraception.
- •2.Willing and able to provide a blood sample just prior to vaccination, 21-28 days post each dose and roughly 6 months post-vaccination.
- •3.Has not received influenza vaccine for the 2022 season
- •4.No known contraindications for influenza vaccination.
- •5.Willing to provide current mobile phone number for SMS reminders
排除标准
- •1.Known contraindication(s) for QIV (e.g. hypersensitivity to vaccine component (including eggs)).
- •2.Recent stem cell transplant (less than 12 months)
- •3.Hypogammaglobulinaemia on immunoglobulin replacement
- •4.Recently (within last 7 days) unwell with a fever above 38°C.
- •5. Prior participation in the study (i.e. during the 2022 enrolment year)
研究者
相似试验
尚未招募
4 期
A trial to study role of influenza vaccine in reducing heart attack, stroke, hospitalisation and death in patients of heart failure.CTRI/2016/07/007081McMaster University3,500
已完成
不适用
Clinical study of influenza vaccine in infants; dose and immunogenicityinfluenzaJPRN-UMIN000000494The Research Foundation for Microbial Diseases of Osaka University200
进行中（未招募）
1 期
A Study Promoting the Influenza Response in the ElderlyThe trial is aimed to improve the efficiency of the seasonal influenza vaccine. Healthy volunteers who are positive for cytomegalovirus (CMV) will be recruited and given anti-viral treatment. We hypothesise that this will reduce their viral load and thereby reduce the proportion of T cells committed to CMV. This will then facilitate the development of an optimal response against the influenza vaccine.EUCTR2011-000092-13-GB
尚未招募
不适用
Efficacy and effectiveness of influenza vaccine and pneumococcal conjugated vaccine - 13 (PCV13) in patients with chronic kidney diseaseInfluenza vaccine13-valent pneumococcal vaccinechronic kidney diseaseschronic kidney diseasepneumoniaTCTR20160609002Queen Saovabha Memorial Institute, the Thai Redcross society1,584
已完成
不适用
Immunogenicity and safety of conventional influenza vaccine in patients with type 2 diabetesCertain infectious and parasitic diseasesKCT0001423Transgovernmental Enterprise for Pandemic Influenza in Korea236